Campath-1H therapy in refractory ocular inflammatory disease.
BACKGROUND: Standard therapy for severe, immune mediated, ocular inflammation has significant side effects, and may fail to control the disease. T cell directed monoclonal antibody (mAb) therapy can provide long term remission of inflammatory disease in experimental models. The Campath-1H mAb was a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2000
|
| _version_ | 1797095298224357376 |
|---|---|
| author | Dick, A Meyer, P James, T Forrester, J Hale, G Waldmann, H Isaacs, J |
| author_facet | Dick, A Meyer, P James, T Forrester, J Hale, G Waldmann, H Isaacs, J |
| author_sort | Dick, A |
| collection | OXFORD |
| description | BACKGROUND: Standard therapy for severe, immune mediated, ocular inflammation has significant side effects, and may fail to control the disease. T cell directed monoclonal antibody (mAb) therapy can provide long term remission of inflammatory disease in experimental models. The Campath-1H mAb was administered to patients with severe, refractory, ocular inflammation. METHODS: 10 patients with severe, refractory, non-infectious ocular inflammatory disease were treated with Campath-1H mAb. This is a fully humanised mAb which recognises the pan-lymphocyte antigen CD52. RESULTS AND DISCUSSION: Following Campath-1H therapy, all 10 patients showed an initial resolution of their ocular symptoms and signs. Long lasting remissions were achieved in eight patients, in whom baseline immunosuppression could subsequently be reduced to minimal levels. The possible mechanisms of action of Campath-1H therapy are discussed. |
| first_indexed | 2024-03-07T04:25:52Z |
| format | Journal article |
| id | oxford-uuid:cc97dc49-e53c-47bb-95e5-4b962d132a49 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:25:52Z |
| publishDate | 2000 |
| record_format | dspace |
| spelling | oxford-uuid:cc97dc49-e53c-47bb-95e5-4b962d132a492022-03-27T07:23:06ZCampath-1H therapy in refractory ocular inflammatory disease.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cc97dc49-e53c-47bb-95e5-4b962d132a49EnglishSymplectic Elements at Oxford2000Dick, AMeyer, PJames, TForrester, JHale, GWaldmann, HIsaacs, J BACKGROUND: Standard therapy for severe, immune mediated, ocular inflammation has significant side effects, and may fail to control the disease. T cell directed monoclonal antibody (mAb) therapy can provide long term remission of inflammatory disease in experimental models. The Campath-1H mAb was administered to patients with severe, refractory, ocular inflammation. METHODS: 10 patients with severe, refractory, non-infectious ocular inflammatory disease were treated with Campath-1H mAb. This is a fully humanised mAb which recognises the pan-lymphocyte antigen CD52. RESULTS AND DISCUSSION: Following Campath-1H therapy, all 10 patients showed an initial resolution of their ocular symptoms and signs. Long lasting remissions were achieved in eight patients, in whom baseline immunosuppression could subsequently be reduced to minimal levels. The possible mechanisms of action of Campath-1H therapy are discussed. |
| spellingShingle | Dick, A Meyer, P James, T Forrester, J Hale, G Waldmann, H Isaacs, J Campath-1H therapy in refractory ocular inflammatory disease. |
| title | Campath-1H therapy in refractory ocular inflammatory disease. |
| title_full | Campath-1H therapy in refractory ocular inflammatory disease. |
| title_fullStr | Campath-1H therapy in refractory ocular inflammatory disease. |
| title_full_unstemmed | Campath-1H therapy in refractory ocular inflammatory disease. |
| title_short | Campath-1H therapy in refractory ocular inflammatory disease. |
| title_sort | campath 1h therapy in refractory ocular inflammatory disease |
| work_keys_str_mv | AT dicka campath1htherapyinrefractoryocularinflammatorydisease AT meyerp campath1htherapyinrefractoryocularinflammatorydisease AT jamest campath1htherapyinrefractoryocularinflammatorydisease AT forresterj campath1htherapyinrefractoryocularinflammatorydisease AT haleg campath1htherapyinrefractoryocularinflammatorydisease AT waldmannh campath1htherapyinrefractoryocularinflammatorydisease AT isaacsj campath1htherapyinrefractoryocularinflammatorydisease |